Exchange: NASDAQ·Updated 07:30 PM EDT

ONC News

News
all
press releases
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 14.31% on an annualized basis producing an average annual return of 28.04%. Currently, BeOne Medicines has a market capitalization ofread more...
Benzinga
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today
BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 14.31% on an annualized basis producing an average annual return of 28.04%. Currently, BeOne Medicines has a market capitalization ofread more...
Benzinga
More News
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 2327...
Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA (tislelizumab) plus...
Business Wire
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with...
Business Wire
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations...
Business Wire
All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy
BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
New Strong Buy Stocks for October 15th
KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.
Zacks
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
BeiGene (NASDAQ:ONC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data andread more...
Benzinga
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.
Stocktwits

Advertisement|Remove ads.